36.19
price up icon0.11%   0.04
after-market アフターアワーズ: 36.19
loading
前日終値:
$36.15
開ける:
$36.03
24時間の取引高:
2.26M
Relative Volume:
0.85
時価総額:
$10.00B
収益:
$2.08B
当期純損益:
$466.92M
株価収益率:
23.20
EPS:
1.56
ネットキャッシュフロー:
$404.94M
1週間 パフォーマンス:
+5.02%
1か月 パフォーマンス:
-2.24%
6か月 パフォーマンス:
+24.54%
1年 パフォーマンス:
+58.24%
1日の値動き範囲:
Value
$35.73
$36.48
1週間の範囲:
Value
$34.16
$36.67
52週間の値動き範囲:
Value
$20.14
$40.02

Exelixis Inc Stock (EXEL) Company Profile

Name
名前
Exelixis Inc
Name
セクター
Healthcare (1151)
Name
電話
(650) 837-7000
Name
住所
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
職員
1,147
Name
Twitter
@exelixisinc
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
EXEL's Discussions on Twitter

EXEL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
EXEL
Exelixis Inc
36.19 10.00B 2.08B 466.92M 404.94M 1.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 ダウングレード Wells Fargo Overweight → Equal Weight
2025-01-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-01-24 ダウングレード Oppenheimer Outperform → Perform
2024-12-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-12-17 ダウングレード BofA Securities Buy → Neutral
2024-10-16 繰り返されました RBC Capital Mkts Outperform
2024-09-19 開始されました UBS Neutral
2024-04-11 ダウングレード Barclays Overweight → Equal Weight
2023-12-19 開始されました BTIG Research Buy
2023-12-15 開始されました Citigroup Buy
2023-09-26 開始されました H.C. Wainwright Buy
2023-08-22 繰り返されました Oppenheimer Outperform
2023-08-08 開始されました SVB Securities Market Perform
2023-07-11 再開されました Morgan Stanley Equal-Weight
2023-05-10 再開されました Piper Sandler Overweight
2023-03-09 開始されました Wells Fargo Overweight
2023-01-26 開始されました Credit Suisse Outperform
2022-10-18 開始されました JMP Securities Mkt Outperform
2022-06-24 開始されました BMO Capital Markets Outperform
2021-11-19 開始されました Piper Sandler Overweight
2021-11-03 再開されました Jefferies Buy
2021-10-07 開始されました Jefferies Buy
2021-08-06 繰り返されました H.C. Wainwright Buy
2021-06-15 開始されました H.C. Wainwright Buy
2021-05-18 再開されました Goldman Sell
2021-03-31 開始されました Credit Suisse Outperform
2021-03-12 開始されました Wolfe Research Outperform
2020-03-04 開始されました Barclays Overweight
2020-01-13 開始されました SunTrust Buy
2019-11-13 開始されました BofA/Merrill Buy
2019-03-18 アップグレード Morgan Stanley Underweight → Equal-Weight
2018-09-17 開始されました Goldman Neutral
2018-09-10 開始されました Morgan Stanley Underweight
2018-05-11 繰り返されました Needham Buy
2017-10-17 繰り返されました Needham Buy
2017-10-17 繰り返されました RBC Capital Mkts Outperform
2017-10-16 繰り返されました SunTrust Buy
2017-09-22 ダウングレード Leerink Partners Outperform → Mkt Perform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-09-12 繰り返されました Needham Buy
2017-07-14 開始されました SunTrust Buy
2017-03-31 開始されました Needham Buy
2017-03-16 開始されました Oppenheimer Perform
2017-02-28 ダウングレード Stifel Buy → Hold
2016-11-03 開始されました Deutsche Bank Buy
2016-10-10 アップグレード Piper Jaffray Neutral → Overweight
2016-09-15 繰り返されました Stifel Buy
すべてを表示

Exelixis Inc (EXEL) 最新ニュース

pulisher
Apr 17, 2025

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

Citizens JMP reiterates Exelixis stock with $41 target By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Summit Investment Advisors Inc. - MarketBeat

Apr 17, 2025
pulisher
Apr 16, 2025

Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings - simplywall.st

Apr 16, 2025
pulisher
Apr 16, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

(EXEL) Investment Analysis - news.stocktradersdaily.com

Apr 16, 2025
pulisher
Apr 11, 2025

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca

Apr 10, 2025
pulisher
Apr 09, 2025

Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis - openPR.com

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Exelixis stock with $42 target By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Exelixis stock with $42 target - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

Apr 08, 2025
pulisher
Apr 05, 2025

Exelixis (EXEL) Gets a Buy from RBC Capital - The Globe and Mail

Apr 05, 2025
pulisher
Apr 03, 2025

The Smartest Biotech Stocks to Buy With $50 - The Motley Fool

Apr 03, 2025
pulisher
Apr 03, 2025

FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Exelixis Launches Special Equity Award Program - TipRanks

Mar 31, 2025
pulisher
Mar 30, 2025

(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 30, 2025
pulisher
Mar 29, 2025

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis stock holds $40 target post FDA nod - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - Yahoo

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView

Mar 26, 2025

Exelixis Inc (EXEL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):